Table 1. Characteristics of the studies included in the meta-analysis.
| First author | Year | Ethnicity | Tumor type | case | control | Genotyping medthod | Source of control | No. of SNP | cancer risk |
|---|---|---|---|---|---|---|---|---|---|
| Hou | 2015 | Asian | GC | 326 | 326 | MassARRAY | Population | 1, 2 | No.1 yes |
| Nemati | 2015 | Caucasian | CRC | 202 | 203 | PCR-RFLP | Hospital | 1*, 2 | yes |
| Gao | 2015 | Asian | GC | 572 | 572 | PCR–RFLP | Hospital | 1, 2* | No.2 yes |
| Lv | 2015 | Asian | CC | 264 | 264 | PCR–RFLP | Population | 1, 2* | No.1 yes |
| Lee | 2015 | Asian | PTC | 94 | 260 | TaqMan | Population | 1 | no risk |
| Xi | 2015 | Asian | HCC | 155 | 171 | PCR–RFLP | Hospital | 1, 2 | no risk |
| Wang | 2014 | Asian | GC | 462 | 462 | PCR–RFLP | Population | 1, 2 | No.1 yes |
| Wróbel | 2014 | Caucasian | AML | 62 | 125 | PCR–RFLP | Population | 1, 2 | No.2 yes |
| Omrane | 2014 | Caucasian | CRC | 102 | 139 | TaqMan | Population | 1 | yes |
| Omrane | 2014 | Caucasian | CRC | 102 | 139 | TaqMan | Population | 2 | yes |
| Yin | 2014 | Asian | EC | 380 | 380 | SNPscan | Hospital | 1 | yes |
| Li | 2014 | Asian | HCC | 395 | 174 | PCR–RFLP | Hospital | 1 | yes |
| Kaabachi | 2014 | Caucasian | LC | 239 | 258 | PCR–RFLP | Population | 1, 2 | No.2 yes |
| Zhu | 2014 | Asian | GC | 311 | 611 | MassARRAY | Hospital | 1, 2* | No.1 yes |
| Zhang | 2014 | Asian | GC | 260 | 512 | MassARRAY | Hospital | 1*, 2* | yes |
| Bi | 2014 | Asian | GC | 99 | 150 | PCR-RFLP | Hospital | 1, 2 | no risk |
| Rafiei | 2013 | Caucasian | GC | 161 | 171 | PCR–RFLP | Hospital | 1 | yes |
| Zhou | 2013 | Asian | BLC | 301 | 446 | TaqMan | Hospital | 1, 2 | yes |
| Arisawa | 2012 | Asian | GC | 337 | 587 | PCR-SSCP | Hospital | 1 | yes |
| Quan | 2012 | Asian | CC | 311 | 463 | TaqMan | Hospital | 1, 2 | No.1 yes |
| Wang | 2012 | Asian | BC | 491 | 502 | SNaPshot | Population | 1, 2 | No.1 yes |
| Ruan | 2012 | Asian | OC | 92 | 38 | PCR-RFLP | Hospital | 1*, 2* | no risk |
| Chen | 2010 | Asian | GC | 1042 | 1090 | TaqMan | Population | 1 | no risk |
| Wu | 2010 | Asian | GC | 1010 | 800 | PCR–RFLP | Population | 1, 2 | No.2 yes |
| Luo | 2010 | Asian | GC | 24 | 50 | PCR-RFLP | Hospital | 1*, 2 | No.1 yes |
| Shibata | 2009 | Asian | GC | 287 | 524 | PCR–SSCP | Hospital | 1*, 2 | No.1 yes |
*The P-values of the Hardy-Weinberg equilibrium test of control group less than 0.05.
CRC: colorectal cancer; GC: gastric cancer; CC: cervical cancer; PTC: papillary thyroid cancer; HCC: hepatocellular carcinoma; LC: lung cancer; AML: acute myeloid leukemia; EC: esophageal cancer; BLC: bladder cancer; BC: breast cancer; OC: ovarian cancer; NA: not available; PCR-RFLP: polymerase chain reaction restriction fragment length polymorphism; SSCP: single strand conformation polymorphism; SNP: single-nucleotide polymorphisms; No. of SNP: No.1: rs2275913, No.2: rs763780.